Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04293094




Registration number
NCT04293094
Ethics application status
Date submitted
2/03/2020
Date registered
3/03/2020
Date last updated
24/08/2023

Titles & IDs
Public title
Study of AMG 650 in Adult Participants With Advanced Solid Tumors
Scientific title
A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors
Secondary ID [1] 0 0
20190131
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Advanced Solid Tumors 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - AMG 650

Experimental: Dose Exploration Phase - Participants will receive AMG 650 in 1 of 3 alternative schedules. The maximum tolerated dose (MTD) of each schedule will be estimated using isotonic regression (Ji et al, 2010). The Recommended Phase 2 Dose (RP2D) may be identified based on emerging safety, efficacy, and pharmacodynamics (PD) data prior to reaching an MTD.

Experimental: Dose Expansion Phase Group 1: TNBC - Participants with locally advanced or metastatic triple negative breast cancer (TNBC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.

Experimental: Dose Expansion Phase Group 2: HGSOC - Participants with locally advanced or metastatic high grade serous ovarian cancer (HGSOC), will be administered with the preliminary RP2D identified from the dose exploration part of the study.


Treatment: Drugs: AMG 650
AMG 650 administered orally as a tablet.
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Number of Participants with Dose Limiting Toxicities (DLTs)
Timepoint [1] 0 0
Up to 12 months
Primary outcome [2] 0 0
Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Timepoint [2] 0 0
Up to 24 months
Primary outcome [3] 0 0
Number of Participants with Serious Adverse Events (SAEs)
Timepoint [3] 0 0
Up to 24 months
Primary outcome [4] 0 0
Number of Participants with Treatment-related Adverse Events
Timepoint [4] 0 0
Up to 24 months
Primary outcome [5] 0 0
Number of Participants Who Experience a Clinically Significant Change from Baseline in Vital Sign Measurement
Timepoint [5] 0 0
Up to 24 months
Primary outcome [6] 0 0
Number of Participants Who Experience a Clinically Significant Change from Baseline in Electrocardiogram (ECGs) Measurement
Timepoint [6] 0 0
Up to 24 months
Primary outcome [7] 0 0
Number of Participants Who Experience a Clinically Significant Change from Baseline in Clinical Laboratory Tests
Timepoint [7] 0 0
Up to 24 months
Secondary outcome [1] 0 0
Objective Response Rate (ORR)
Timepoint [1] 0 0
Up to 24 months
Secondary outcome [2] 0 0
Duration of Response (DOR)
Timepoint [2] 0 0
Up to 24 months
Secondary outcome [3] 0 0
Progression-free Survival (PFS)
Timepoint [3] 0 0
Up to 24 months
Secondary outcome [4] 0 0
Clinical Benefit Rate (CBR)
Timepoint [4] 0 0
Up to 24 months
Secondary outcome [5] 0 0
Time to Response (TTR)
Timepoint [5] 0 0
Up to 24 months
Secondary outcome [6] 0 0
Time to Progression (TTP)
Timepoint [6] 0 0
Up to 24 months
Secondary outcome [7] 0 0
Overall Survival (OS)
Timepoint [7] 0 0
Up to 24 months
Secondary outcome [8] 0 0
Maximum Plasma Concentration (Cmax) of AMG 650
Timepoint [8] 0 0
Up to 24 months
Secondary outcome [9] 0 0
Time to Maximum Plasma Concentration (Tmax) of AMG 650
Timepoint [9] 0 0
Up to 24 months
Secondary outcome [10] 0 0
Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval for AMG 650
Timepoint [10] 0 0
Up to 24 months

Eligibility
Key inclusion criteria
- Male and female = 18 years old

- Triple Negative Breast Cancer participants only: Participant must have histologically
or cytologically confirmed metastatic or locally recurrent estrogen receptor
(ER)-negative (<1% by immunohistochemistry [IHC]), progesterone receptor (PR)-negative
(<1% IHC) and human epidermal growth factor receptor 2 (Her2)-negative (either
fluorescent in situ hybridisation [FISH] negative, 0 or 1+ by IHC, or IHC2+ and FISH
negative per ASCO/CAP definition) breast cancer. Participant must be
relapsed/refractory to at least one line of systemic chemotherapy in the metastatic
setting (excluding neoadjuvant or adjuvant chemotherapies) or intolerant of existing
therapy(ies) known to provide clinical benefit or have no other available treatment
options. Prior exposure to an immune checkpoint inhibitor is allowed.

- Platinum-Resistant High Grade Serous Ovarian Cancer, primary peritoneal cancer and/or
fallopian-tube cancer participants only: Participant must have histologically or
cytologically confirmed diagnosis of metastatic or unresectable high grade serous
ovarian cancer, with platinum-resistance defined as progression during or within 6
months of a platinum-containing regimen, with no other treatment option available.
Prior exposure to platinum-resistant recurrence therapy is allowed.

- Serous Endometrial Cancer participants only (Dose Exploration only): Participant must
have histologically or cytologically confirmed diagnosis of metastatic or recurrent
serous endometrial cancer, and be relapsed/refractory to at least one line of systemic
therapy in the metastatic/recurrent setting or intolerant of existing therapy(ies)
known to provide clinical benefit for their condition.

- Participants with advanced or metastatic solid tumor with TP53MUT (Dose Exploration
only, as assessed by local testing) that is unresectable and relapsed/refractory to at
least one line of systemic chemotherapy or intolerant.

- TNBC participants only (Dose Expansion): Progressed on no more than 3 prior lines of
systemic therapy for locally advanced or metastatic disease (not including adjuvant or
neo-adjuvant). Systemic therapy with poly ADP ribose polymerase (PARP) inhibitor will
be counted as one line of therapy.

- HGSOC participants only (Dose Expansion): Progressed on no more than 5 prior lines of
systemic therapy for locally advanced or metastatic disease (not including adjuvant or
neo-adjuvant). Systemic therapy with (PARP) inhibitor will be counted as one line of
therapy. Induction followed by maintenance will be counted as one line of therapy.
Minimum age
18 Years
Maximum age
99 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Untreated or symptomatic brain metastases and leptomeningeal disease (exception:
benign asymptomatic tumors are permitted).

- Current primary CNS tumor, hematological malignancies or lymphoma.

- Uncontrolled pleural effusions(s), pericardial effusion, or ascites.

- Gastrointestinal (GI) tract disease causing the inability to take oral medication.

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/03/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
15/02/2023
Sample size
Target
Accrual to date
Final
66
Recruitment in Australia
Recruitment state(s)
SA,VIC
Recruitment hospital [1] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [2] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
5011 - Woodville South
Recruitment postcode(s) [2] 0 0
3000 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Indiana
Country [3] 0 0
United States of America
State/province [3] 0 0
Minnesota
Country [4] 0 0
United States of America
State/province [4] 0 0
Missouri
Country [5] 0 0
United States of America
State/province [5] 0 0
New York
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Oklahoma
Country [8] 0 0
United States of America
State/province [8] 0 0
Oregon
Country [9] 0 0
United States of America
State/province [9] 0 0
Tennessee
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
Belgium
State/province [11] 0 0
Leuven
Country [12] 0 0
Canada
State/province [12] 0 0
Alberta
Country [13] 0 0
Canada
State/province [13] 0 0
Ontario
Country [14] 0 0
Italy
State/province [14] 0 0
Milano
Country [15] 0 0
Japan
State/province [15] 0 0
Aichi
Country [16] 0 0
Japan
State/province [16] 0 0
Chiba
Country [17] 0 0
Spain
State/province [17] 0 0
Madrid

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Volastra Therapeutics, Inc.
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Amgen
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
To evaluate the safety and tolerability of AMG 650 in adult participants and to determine the
maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D).
Trial website
https://clinicaltrials.gov/ct2/show/NCT04293094
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries